Skip to content
AnalystLens

Strategy 8-K Report, Corporate Update (Jul 5, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed July 5, 2024
Period End
July 5, 2024
In the record · 2016–202610-K1110-Q338-K265

MSTR filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 265 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jul ’20Jul ’20
  2. Material agreement8-K · Sep ’22Sep ’22
  3. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed July 5, 2024. Cited figures are marked; the original filing is the authoritative source.

This Form 8-K, filed by MicroStrategy Incorporated (now Strategy Inc) under Item 8.01 (Other Events), reports that its wholly owned subsidiary, MicroStrategy Brasil Ltda., signed a leniency agreement on July 4, 2024 with Brazil's Federal Comptroller General (CGU) and Federal General Attorney's Office (AGU).

The agreement stems from a 2018 voluntary disclosure by the subsidiary of an internal review finding that it failed or likely failed to comply with Brazilian procurement regulations in selling business intelligence products and services to Brazilian government clients between 2014 and 2018. Under the agreement, MicroStrategy Brasil agreed to pay approximately BRL 6.16 million (or USD 1.1 million), committed to compliance program undertakings, and was granted immunity from debarment and other sanctions. The company states it previously established a USD 1.2 million reserve in its financial statements for these matters.

The CGU will also dismiss a pending administrative action against the subsidiary over alleged procurement violations. The company does not expect the leniency agreement to adversely affect MicroStrategy Brasil's operations, which continue in the ordinary course. The filing also references a separate 2023 leniency agreement with Brazil's SG/CADE, which the company likewise does not expect to adversely affect operations.

Key Highlights

  1. MicroStrategy Brasil Ltda., a wholly owned subsidiary, signed a leniency agreement with Brazil's CGU and AGU on July 4, 2024.
  2. The subsidiary agreed to pay approximately BRL 6.16 million (about USD 1.1 million) under the agreement.
  3. The company previously established a USD 1.2 million reserve in its financial statements for these matters.
  4. The subsidiary received immunity from debarment and other sanctions and committed to compliance program improvements.
  5. The CGU will dismiss its pending administrative action over alleged procurement violations in the sale of business intelligence products to Brazilian government clients (2014-2018).
  6. The company does not expect the agreement to adversely impact MicroStrategy Brasil's operations, which continue in the ordinary course.
  7. The filing references a separate leniency agreement with Brazil's SG/CADE, announced in January 2023.

Frequently Asked Questions

  1. What led to the leniency agreement?

    An internal review initiated in 2018 found that MicroStrategy Brasil failed or likely failed to comply with Brazilian procurement regulations when selling business intelligence products and services to Brazilian government clients between 2014 and 2018. The subsidiary voluntarily disclosed this information to the CGU and AGU in 2018 and took remedial actions, including terminating several employees involved and restructuring its Brazilian operations.

  2. How much will the subsidiary pay, and was it already reserved for?

    The subsidiary agreed to pay approximately BRL 6.16 million (about USD 1.1 million). The company states it previously established a USD 1.2 million reserve in its financial statements in respect of these matters.

  3. Will this agreement affect MicroStrategy Brasil's business?

    The company does not expect the leniency agreement to adversely impact MicroStrategy Brasil's operations, and the subsidiary continues to conduct its business in the ordinary course.

  4. What other regulatory matters are referenced in the filing?

    The filing references a separate leniency agreement with Brazil's SG/CADE, announced in January 2023, which resulted from the same 2018 internal review. The company does not expect it to adversely affect operations.